Designing a National Education Program to support quality use of medicines in Inflammatory Bowel Disease
The program aims to achieve better patient health outcomes, support optimal use of biological and small molecule medicines and contribute…
What do Rheumatologists think and do in the management of Inflammatory Arthritis: A Baseline Survey
Presented at ARA Annual Scientific Meeting May 2021
Patterns of use of b/tsDMARDS and other medications for with Rheumatoid Arthritis: a retrospective study using PBS data
Presented at ARA Annual Scientific Meeting May 2021 Aims to describe prescribing patterns for biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs)…
Initiating a National Consortium Approach to support optimal use of bDMARDs
Poster presented at ARA Annual Scientific Meeting May 2021
Supporting safe practices for low-dose methotrexate – NMS 2021
Inconsistent practices and information about the use of low-dose methotrexate for inflammatory diseases results in unfounded patient and health professional…
Assessment and evaluation of high cost medicines in Australian public hospitals
Poster presentation at SHPA Medicines Management Conference 2015 aiming to describe the decision-making process for access to High Cost Medicines…
Overseeing Biosimilar Use: Guiding Principles for the governance of biological and biosimilar medicines in Australian hospitals
Poster presentation at SHPA Medicines Management Conference 2015. This poster aims to provide guidance for good governance and decision-making in…
Supporting the Quality Use of Medicines across the acute-care sector
Editorial article in the Internal Medicine Journal 2015
Off -label prescribing – Letter to the Editor MJA
Rethinking medicines decision-making for off-label use of medicines conference presentation
Poster presentation at ASCEPT conference in 2013. CATAG developed a consensus framework to support the quality use of off-label medicines…